Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

12.01.21	SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer (GlobeNewswire)
12.01.21	Biond Biologics, Sanofi Announce Global Licensing Agreement For BND-22 - Quick Facts (RTTNews)
11.01.21	Sanofi To Acquire Kymab Adding KY1005 To Its Pipeline - Quick Facts (RTTNews)
11.01.21	Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L (GlobeNewswire)
07.01.21	Nurix Therapeutics To Receive Additional $22 Mln On Sanofi Collaboration Expansion - Quick Facts (RTTNews)
17.12.20	Availability of the Q4 2020 Memorandum for modelling purposes (GlobeNewswire)
15.12.20	Sanofi Renews Partnership With WHO - Quick Facts (RTTNews)
15.12.20	Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030 (GlobeNewswire)
11.12.20	Sanofi: CHMP Adopts Positive Opinion For Additional Indication For Plavix (RTTNews)
11.12.20	CHMP recommends approval of Plavix® (clopidogrel) with aspirin in adults for certain types of strokes (GlobeNewswire)
11.12.20	Sanofi, GSK Delay COVID-19 Vaccine Program Due To Low Immune Response In Elderly People (RTTNews)
11.12.20	Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly (GlobeNewswire)
09.12.20	Sanofi, Kiadis Satisfy Competition Condition Regarding Tender Offer (RTTNews)
09.12.20	Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities (GlobeNewswire)
30.11.20	Sanofi, Kiadis Issue Update On Public Offer - Quick Facts (RTTNews)
30.11.20	Regeneron Reports Approval Of Dupixent In Europe For Children With Severe Atopic Dermatitis (RTTNews)
30.11.20	Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis (GlobeNewswire)
23.11.20	European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older (GlobeNewswire)
19.11.20	Sanofi: European Commission Approves Supemtek Recombinant Influenza Vaccine (RTTNews)
18.11.20	European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older (GlobeNewswire)
18.11.20	Sanofi: Rilzabrutinib Granted Fast Track Designation - Quick Facts (RTTNews)
18.11.20	Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia (GlobeNewswire)
18.11.20	Sanofi: FDA Grants Priority Review For Avalglucosidase Alfa - Quick Facts (RTTNews)
18.11.20	FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease (GlobeNewswire)
14.11.20	FDA Issues CRL For Sanofi's Sutimlimab Due To Deficiencies In Third-party Manufacturing Facility (RTTNews)
14.11.20	FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease (GlobeNewswire)
08.11.20	Week Ahead In Pharma: FDA Decisions, SITC Presentations, 13D SEC Filing (RTTNews)
02.11.20	Sanofi Offers To Buy Dutch NK Cell Therapy Developer Kiadis For EUR 5.45/share (RTTNews)
02.11.20	Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products (GlobeNewswire)
30.10.20	Regeneron : IDMC Recommends To Hold Enrollment In Hospitalized High Risk COVID-19 Patients (RTTNews)
29.10.20	European Patent Office Rules In Favor Of Sanofi, Regeneron On Praluent (RTTNews)
29.10.20	European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab) (GlobeNewswire)
29.10.20	Sanofi Q3 Business Net Income Rises; Increases 2020 Business EPS Guidance (RTTNews)
29.10.20	Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology (GlobeNewswire)
28.10.20	Sanofi, GSK Intend To Supply 200 Mln Doses Of COVID-19 Vaccine To COVAX Facility (RTTNews)
28.10.20	Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine (GlobeNewswire)
26.10.20	Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings (GlobeNewswire)
26.10.20	Biotech Stocks Facing FDA Decision In November 2020 (RTTNews)
16.10.20	CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis (GlobeNewswire)
16.10.20	SNY/TBIO Move COVID-19 Vaccine Into Clinic, AVXL's PDD Study Promising, EIGR On Watch (RTTNews)
15.10.20	Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies (GlobeNewswire)
14.10.20	LLY Pauses COVID-19 Antibody Trial, JNJ Boosts Annual Outlook, Double Whammy For GOSS (RTTNews)
13.10.20	Regeneron: Phase 3 Trial Shows Dupixent Significantly Reduces Severe Asthma Attacks In Children (RTTNews)
13.10.20	Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial (GlobeNewswire)
02.10.20	Europe Accepts Sanofi's Regulatory Submission For Enzyme Replacement Therapy For Pompe Disease (RTTNews)
02.10.20	EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease (GlobeNewswire)
28.09.20	Sanofi completes Principia Biopharma Inc. acquisition (GlobeNewswire)
25.09.20	Availability of the Q3 2020 Memorandum for modelling purposes (GlobeNewswire)
22.09.20	Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine (GlobeNewswire)
22.09.20	Sanofi - Principia Biopharma Deal Receives U.S. Antitrust Approval (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

29.12.24		Novartis-Aktie: Novartis muss sich erneut Schmiergeld-Vorwürfen stellen
29.12.24		Roche-CEO bescheinigt Pharmakonzern gesundes Geschäft
27.12.24		Anleger in New York halten sich zurück: Dow Jones beendet die Freitagssitzung im Minus
27.12.24		BioNTech und Pfizer zahlen Milliardenbetrag für Impfstoffvergleich in USA - BioNTech-Aktie fester
27.12.24		Dow Jones aktuell: Dow Jones verliert am Freitagnachmittag
27.12.24		Schwacher Wochentag in New York: Dow Jones verbucht am Freitagmittag Verluste
27.12.24		Freitagshandel in Frankfurt: LUS-DAX zeigt sich letztendlich fester

29.12.24

Novartis-Aktie: Novartis muss sich erneut Schmiergeld-Vorwürfen stellen

29.12.24

Roche-CEO bescheinigt Pharmakonzern gesundes Geschäft

27.12.24

Anleger in New York halten sich zurück: Dow Jones beendet die Freitagssitzung im Minus

27.12.24

BioNTech und Pfizer zahlen Milliardenbetrag für Impfstoffvergleich in USA - BioNTech-Aktie fester

27.12.24

Dow Jones aktuell: Dow Jones verliert am Freitagnachmittag

27.12.24

Schwacher Wochentag in New York: Dow Jones verbucht am Freitagmittag Verluste

27.12.24

Freitagshandel in Frankfurt: LUS-DAX zeigt sich letztendlich fester

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Sanofi S.A.

Aktien Top/Flop

Sanofi Peer Group Nachrichten

Meistgelesene Nachrichten